Diagnostic value of PET/CT with
11C-methionine
18F-fluorothymidine
Glioma
IDH1 mutation
PET/CT
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
07 May 2020
07 May 2020
Historique:
received:
22
02
2020
accepted:
16
04
2020
entrez:
9
5
2020
pubmed:
10
5
2020
medline:
10
5
2020
Statut:
epublish
Résumé
The molecular features of isocitrate dehydrogenase (IDH) mutation and chromosome 1p and 19q (1p/19q) codeletion status have pivotal role for differentiating gliomas and have been integrated in the World Health Organization (WHO) classification in 2016. Positron emission tomography (PET) with 3'-deoxy-3'-[ In total, 81 patients with newly diagnosed supratentorial glioma were enrolled in this study. They underwent PET/CT studies with MET and FLT before surgery. The molecular features and histopathological diagnosis based on the 2016 WHO classification were determined using surgical specimens. The ratios of the maximum standardized uptake value (SUV) of the tumours to the mean SUV of the contralateral cortex (T/N ratios) were calculated on MET-PET/CT and FLT-PET/CT images. The mean T/N ratios of MET-PET/CT and FLT-PET/CT in IDH1-wildtype tumours were significantly higher than those in IDH1-mutant tumours (P < 0.001 and P < 0.001, respectively). Receiver operating characteristic analysis for differentiating IDH1 mutation status showed that the area under the curve of the FLT T/N ratio was significantly larger than that of the MET T/N ratio (P < 0.01). The mean T/N ratio of FLT-PET/CT in IDH1-wildtype tumours was significantly higher than that in IDH1-mutant tumours among grade II and III gliomas (P = 0.005), but this was not the case for MET-PET/CT. Both MET-PET/CT and FLT-PET/CT were able to distinguish between grade II and III gliomas in IDH1-mutant tumours (P = 0.002 and P < 0.001, respectively), but only FLT-PET/CT was able to distinguish between grade III and IV gliomas in IDH1-wildtype tumours (P = 0.029). This study showed that FLT-PET/CT can be used to determine the IDH1 mutation status and evaluate glioma grade more accurately than MET-PET/CT. FLT-PET/CT can improve glioma differentiation based on the 2016 WHO classification, but caution must be paid for tumours without contrast enhancement and further studies should be conducted with more cases.
Sections du résumé
BACKGROUND
BACKGROUND
The molecular features of isocitrate dehydrogenase (IDH) mutation and chromosome 1p and 19q (1p/19q) codeletion status have pivotal role for differentiating gliomas and have been integrated in the World Health Organization (WHO) classification in 2016. Positron emission tomography (PET) with 3'-deoxy-3'-[
METHODS
METHODS
In total, 81 patients with newly diagnosed supratentorial glioma were enrolled in this study. They underwent PET/CT studies with MET and FLT before surgery. The molecular features and histopathological diagnosis based on the 2016 WHO classification were determined using surgical specimens. The ratios of the maximum standardized uptake value (SUV) of the tumours to the mean SUV of the contralateral cortex (T/N ratios) were calculated on MET-PET/CT and FLT-PET/CT images.
RESULTS
RESULTS
The mean T/N ratios of MET-PET/CT and FLT-PET/CT in IDH1-wildtype tumours were significantly higher than those in IDH1-mutant tumours (P < 0.001 and P < 0.001, respectively). Receiver operating characteristic analysis for differentiating IDH1 mutation status showed that the area under the curve of the FLT T/N ratio was significantly larger than that of the MET T/N ratio (P < 0.01). The mean T/N ratio of FLT-PET/CT in IDH1-wildtype tumours was significantly higher than that in IDH1-mutant tumours among grade II and III gliomas (P = 0.005), but this was not the case for MET-PET/CT. Both MET-PET/CT and FLT-PET/CT were able to distinguish between grade II and III gliomas in IDH1-mutant tumours (P = 0.002 and P < 0.001, respectively), but only FLT-PET/CT was able to distinguish between grade III and IV gliomas in IDH1-wildtype tumours (P = 0.029).
CONCLUSION
CONCLUSIONS
This study showed that FLT-PET/CT can be used to determine the IDH1 mutation status and evaluate glioma grade more accurately than MET-PET/CT. FLT-PET/CT can improve glioma differentiation based on the 2016 WHO classification, but caution must be paid for tumours without contrast enhancement and further studies should be conducted with more cases.
Identifiants
pubmed: 32382870
doi: 10.1186/s13550-020-00633-1
pii: 10.1186/s13550-020-00633-1
pmc: PMC7205963
doi:
Types de publication
Journal Article
Langues
eng
Pagination
44Subventions
Organisme : Japan Society for the Promotion of Science
ID : Grant-in-Aid for Scientific Research (KAKENHI) (18H02913)
Références
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1678-1684
pubmed: 31102001
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1381-1390
pubmed: 31529264
Neuroimage Clin. 2015 May 29;8:448-54
pubmed: 26106569
J Nucl Med. 2012 Dec;53(12):1904-10
pubmed: 23077112
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):682-94
pubmed: 26537287
Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2009-17
pubmed: 18542957
J Nucl Med. 2005 Dec;46(12):1948-58
pubmed: 16330557
Eur J Nucl Med Mol Imaging. 2015 May;42(6):896-904
pubmed: 25647076
Lancet Oncol. 2014 Aug;15(9):e395-403
pubmed: 25079102
J Neurooncol. 2016 Sep;129(3):505-514
pubmed: 27401154
J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
pubmed: 15977639
Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):175-85
pubmed: 23229746
J Neuropathol Exp Neurol. 2018 Jun 1;77(6):422-425
pubmed: 29444314
J Nucl Med. 2006 Oct;47(10):1612-21
pubmed: 17015896
J Neurooncol. 2019 Jan;141(1):223-233
pubmed: 30467813
J Neurosurg. 2019 Aug 16;:1-10
pubmed: 31419796
J Nucl Med. 2012 Dec;53(12):1911-5
pubmed: 23081994
Lancet Oncol. 2013 Aug;14(9):e370-9
pubmed: 23896276
Neuro Oncol. 2014 Jan;16(1):81-91
pubmed: 24305719
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1155-1164
pubmed: 28110346
Nat Genet. 2015 May;47(5):458-68
pubmed: 25848751
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):443-451
pubmed: 29043400
AJNR Am J Neuroradiol. 2008 Jun;29(6):1176-82
pubmed: 18388218
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1306-1311
pubmed: 28293705
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2015 Apr;129(4):585-96
pubmed: 25701198
Acta Neuropathol. 2015 May;129(5):679-93
pubmed: 25783747
Nat Med. 1998 Nov;4(11):1334-6
pubmed: 9809561
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35
pubmed: 23232505
Semin Nucl Med. 2007 Nov;37(6):429-39
pubmed: 17920350